TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy

Ruitao Lin, Robert L Coleman, Ying Yuan

Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of…